Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial

[1]  J. Petrozzino,et al.  Prevention of treatment-related fluid overload reduces estimated effective cost of prothrombin complex concentrate in patients requiring rapid vitamin K antagonist reversal , 2016, Expert review of pharmacoeconomics & outcomes research.

[2]  B. Hug,et al.  Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial , 2015, The Lancet.

[3]  F. Pomero,et al.  Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage , 2015, Annals of neurology.

[4]  G. Fink,et al.  Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. , 2015, JAMA.

[5]  D. Krieger,et al.  European Stroke Organisation (ESO) Guidelines for the Management of Spontaneous Intracerebral Hemorrhage , 2014, International journal of stroke : official journal of the International Stroke Society.

[6]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[7]  G. Luijckx,et al.  Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate , 2013, Thrombosis and Haemostasis.

[8]  J. Goldstein,et al.  Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding: A Randomized, Plasma-Controlled, Phase IIIb Study , 2013, Circulation.

[9]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[10]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[11]  M. Hennerici,et al.  International Normalised Ratio Normalisation in Patients with Coumarin-Related Intracranial Haemorrhages – the INCH Trial: A Randomised Controlled Multicentre Trial to Compare Safety and Preliminary Efficacy of Fresh Frozen Plasma and Prothrombin Complex – Study Design and Protocol , 2011, International journal of stroke : official journal of the International Stroke Society.

[12]  C. Anderson,et al.  Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2010, Stroke.

[13]  W. Hacke,et al.  Point‐of‐care reversal treatment in phenprocoumon‐related intracerebral hemorrhage , 2010, Annals of neurology.

[14]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[15]  Piotr Pruszczyk,et al.  Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism , 2008 .

[16]  S. Mayer,et al.  Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. , 2008, The New England journal of medicine.

[17]  T. Strowitzki,et al.  Ethische und juristische Aspekte beim Einschluss nicht einwilligungsfähiger Patienten in Akuttherapie-Studien , 2008 .

[18]  J. Alpert,et al.  Universal definition of myocardial infarction. , 2007, European heart journal.

[19]  Susan Regan,et al.  Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation , 2007, Circulation.

[20]  Kevin Weiss,et al.  Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. , 2017, Annals of internal medicine.

[21]  S. Mayer,et al.  Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage , 2007, Stroke.

[22]  S. Greenberg,et al.  Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage , 2004, Neurology.

[23]  M. Kaste,et al.  Acute Treatment of Ischaemic Stroke , 2003, Cerebrovascular Diseases.

[24]  K. Furie,et al.  A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. , 2001, The New England journal of medicine.

[25]  R McBride,et al.  Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. , 1999, Stroke.

[26]  G. Teasdale,et al.  Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. , 1998, Journal of neurotrauma.

[27]  P. Koudstaal,et al.  Grading white matter lesions on CT and MRI: a simple scale. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[28]  J. Marler,et al.  Measurements of acute cerebral infarction: a clinical examination scale. , 1989, Stroke.

[29]  Mahoney Fi,et al.  FUNCTIONAL EVALUATION: THE BARTHEL INDEX. , 1965 .

[30]  W. Dixon.  Simplified Estimation from Censored Normal Samples , 1960 .

[31]  David P. Reardon,et al.  Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center. , 2016, The Journal of emergency medicine.

[32]  J. Broderick,et al.  Early hemorrhage growth in patients with intracerebral hemorrhage. , 1997, Stroke.

[33]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .